Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
624.00    -3.00 (-0.48%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £543.66m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Director/PDMR Shareholding

10 Feb 2023 14:12

RNS Number : 6220P
Victrex PLC
10 February 2023
 

10 February 2023

Victrex plc (the Company)

Grant of Options under the Victrex plc 2015 UK Sharesave Plan

Notification of transactions by directors/persons discharging managerial responsibilities

Victrex plc announces that it has launched two 2023 Save As You Earn Schemes (the "SAYE Scheme"). The SAYE Scheme is an all-employee scheme which gives the opportunity to eligible UK employees to acquire shares at a discount, over 3 or 5 years.

Eligible employees were invited to subscribe for options over the Company's ordinary shares of 1p each ("Shares"), with an exercise price of £13.936 per share representing a 20% discount to the closing mid-market price on 11 January 2023, the day before the invitation to participate was made. The exercise price was calculated in accordance with the rules of the SAYE. The options have a savings start date of 1 April 2023 and will normally be exercisable for 6 month period commencing 1 April 2026 for the 3 Year contract, and 1 April 2028 for the 5 Year contract.

A total of 463 employees elected to participate in the 2023 SAYE Scheme accordingly a total of 374,055 options were granted on 9 February 2023. In consideration of these options, the grantees will make monthly savings during the associated savings contract.

The following Persons Discharging Managerial Responsibility ("PDMRs") have chosen to participate in the 2023 SAYE Scheme:

Name

Position

No. of shares under options granted

Savings Contract Period

Jakob Sigurdsson

Executive Director

2,152

5 Years

Martin Court

Executive Director

645

3 Years

Ian Melling

Executive Director

1,291

3 Years

 

The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below and gives further details on the option grants for directors and PDMRs.

  

 

 

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1.  Jakob Sigurdsson

2.  Martin Court

3.  Ian Melling

2

Reason for the notification

a)

Position/status

Executive Director (PDMR)

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Victrex plc

b)

LEI

213800UYNPHAUNHPXL67

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Option over ordinary shares of 1p each

 

 

GB0009292243

b)

Nature of the transaction

Option granted under the Company's all-employee HMRC approved Save As You Earn scheme (Victrex plc 2015 UK Sharesave Plan) with an exercise price of £13.936.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

£13.936

2,152

2.

£13.936

645

3.

£13.936

1,291

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

N/A

 

e)

Date of the transaction

9 February 2023

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHMZGMZDGMGFZM
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.